HCW Biologics Inc(HCWB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 7:36 AM ET (Korea 9/29 20:36)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -28.42 | Insider Own | 10.2% | Shs Outstand | 2.2M | Perf Week | -4.71% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 8.33% | Insider Trans | 150.99% | Shs Float | 2.0M | Perf Month | -42.59% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -1.08 | Inst Own | 4.63% | Short Float | 0.46% | Perf Quarter | -65.37% |
| Income | -0.02B | P/S | 0.61 | EPS this Y | 95.48% | Inst Trans | -3.39% | Short Ratio | 0.02 | Perf Half Y | -23.96% |
| Sales | 0.01B | P/B | 0.4 | EPS next 5Y | 67.95% | ROA | -79.52% | Short Interest | 0.01M | Perf YTD | -68.75% |
| Book/sh | 4.59 | P/C | 5.51 | EPS past 3/5Y | 13.87% -6.63% | ROE | -600.31% | 52W High | -93.78% ($29.28) | Perf Year | -92.58% |
| Cash/sh | 0.33 | P/FCF | - | Sales past 3/5Y | -79.94% -57.9% | ROIC | -298.06% | 52W Low | 21.33% ($1.50) | Perf 3Y | -99.6% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 70.52% | Gross Margin | 86.99% | Volatility(W/M) | 27.65% 15.82% | Perf 5Y | -99.76% |
| Dividend TTM | - | EV/Sales | 1.47 | Sales Y/Y TTM | 707.02% | Oper. Margin | -90.06% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.06 | EPS Q/Q | 71.57% | Profit Margin | -329.38% | RSI (14) | 35.96 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.06 | Sales Q/Q | 1969.74% | SMA20 | -22.63% ($2.35) | Beta | 2.37 | Target Price | $30 |
| Payout | - | Debt/Eq | 0.88 | Earnings | 2026/8/14 | SMA50 | -32.59% ($2.7) | Rel Volume | 0.28 | Prev Close | $1.93 |
| Employees | 35 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -484.85% - | SMA200 | -63.49% ($4.98) | Avg Volume(3M) | 0.38M | Price | $1.82 |
| IPO | 2021/7/20 | Option/Short | No/Yes | Trades | 790 | Volume | 104,526 | Change | -5.7% |
🧬 A clinical-stage biopharmaceutical company headquartered in Miami, Florida, developing immunotherapy treatments. The company is working on a multifunctional immune cell stimulator (MFICS) platform aimed at treating chronic inflammation and age-related diseases.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded less than usual That is 28% of its average volume.
HCWB has weak earnings and a weak balance sheet
Of every $100 in sales, $90.06 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +95.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $61. Peers typically go for $1,227.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #557 of 592 in the industry
Based on market cap of $4M.
FAQ
What kind of company is HCWB?
HCWB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HCWB?
The market cap of HCWB is approximately $4M, ranking 5,733 within its sector.
What is the 52-week high and low for HCWB?
HCWB has recorded a 52-week high of $29.28 and a low of $1.50.
